Basic research on the biological mechanism of Alzheimer's disease has focused for decades on the age-related aggregation of the amyloid β-protein and its apparent downstream effects on microglia, astrocytes and neurons, including the posttranslational modification of the tau protein that seems necessary for symptom expression. Here, we discuss the highly challenging process of developing disease-modifying therapies and highlight several key areas of current research that are progressing in exciting directions. We conclude that further deep molecular analyses of the disease, including the mechanisms of β-amyloidosis, will enable more effective clinical trials and ultimately achieve the progress that our patients so deserve.

中文翻译：

---

β-淀粉样蛋白及其他蛋白：阿尔茨海默氏病的发展之路。

阿尔茨海默氏病生物学机制的基础研究数十年来一直专注于淀粉样β蛋白的年龄相关聚集及其对小胶质细胞，星形胶质细胞和神经元的明显下游影响，包括tau蛋白的翻译后修饰，这似乎是症状所必需的。表达。在这里，我们讨论了开发疾病改良疗法的极富挑战性的过程，并突出了当前研究的几个关键领域，这些领域正在朝着令人兴奋的方向发展。我们得出的结论是，对该疾病进行更深入的分子分析，包括β-淀粉样变性的机制，将使更有效的临床试验成为可能，并最终实现我们的患者应有的进步。